Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 50 of 2051 entries
View as:

Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)

Phase: N/A Priority: Normal
NCT ID: NCT03396445 Org: User:
Start: 02/18/18 End: 09/27/24 Due: 09/27/25

A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)

Phase: N/A Priority: Normal
NCT ID: NCT00768521 Org: User:
Start: 09/03/08 End: 01/19/09 Due: 01/19/10

Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023)

Phase: N/A Priority: Normal
NCT ID: NCT00095576 Org: User:
Start: 11/30/04 End: 09/30/09 Due: 09/30/10

Safety and Efficacy of Prulifloxacin Versus Placebo in Traveler's Diarrhea

Phase: N/A Priority: Normal
NCT ID: NCT00392574 Org: User:
Start: 08/31/06 End: 03/31/08 Due: 03/31/09

Re-examination Study of EMEND (Aprepitant) (MK-0869-184)

Phase: N/A Priority: Normal
NCT ID: NCT01074255 Org: User:
Start: 04/30/07 End: 10/31/11 Due: 10/31/12

First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)

Phase: N/A Priority: Normal
NCT ID: NCT03189719 Org: User:
Start: 07/25/17 End: 07/10/23 Due: 07/10/24

A Study of MK-6552 in Sleep Deprived Healthy Participants (MK-6552-003)

Phase: N/A Priority: Normal
NCT ID: NCT06619665 Org: User:
Start: 03/19/24 End: 07/16/24 Due: 07/16/25

MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104)

Phase: N/A Priority: Normal
NCT ID: NCT00837577 Org: User:
Start: 02/05/09 End: 08/11/10 Due: 08/11/11

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension

Phase: N/A Priority: Normal
NCT ID: NCT04907227 Org: User:
Start: 09/23/20 End: 07/18/23 Due: 07/18/24

Pilot Feasibility Study With Patients Who Are at High Risk For Developing Invasive Candidiasis in a Critical Care Setting (MK-0991-067)

Phase: N/A Priority: Normal
NCT ID: NCT01045798 Org: User:
Start: 12/31/10 End: 04/30/12 Due: 04/30/13

Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00376584 Org: User:
Start: 07/31/06 End: 01/31/07 Due: 01/31/08

Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042)

Phase: N/A Priority: Normal
NCT ID: NCT04193176 Org: User:
Start: 05/10/20 End: 09/02/22 Due: 09/02/23

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

Phase: N/A Priority: Normal
NCT ID: NCT05064059 Org: User:
Start: 11/10/21 End: 02/21/25 Due: 02/21/26

Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)

Phase: N/A Priority: Normal
NCT ID: NCT03019588 Org: User:
Start: 02/16/17 End: 06/29/21 Due: 06/29/22

Sitagliptin/Metformin (JANUMET) Re-examination Study (0431A-182)

Phase: N/A Priority: Normal
NCT ID: NCT01065766 Org: User:
Start: 03/31/09 End: 05/31/13 Due: 05/31/14

A Placebo-Controlled, Double-Blinded, Randomized Trial of Remicade in Korean Patients With Rheumatoid Arthritis Despite Methotrexate (Study P04280)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00202852 Org: User:
Start: 06/01/05 End: 03/01/06 Due: 03/01/07

SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)

Phase: N/A Priority: Normal
NCT ID: NCT00871546 Org: User:
Start: 03/31/09 End: 12/31/10 Due: 12/31/11

Investigation of V520 in a HIV Vaccine Dose Refinement Study (V520-027)(TERMINATED)

Phase: N/A Priority: Normal
NCT ID: NCT00350623 Org: User:
Start: 10/31/06 End: 05/31/08 Due: 05/31/09

Phase III PEG-Intron in HIV-infected Patients (Study P00738)

Phase: N/A Priority: Normal
NCT ID: NCT00035360 Org: User:
Start: 03/31/02 End: 10/31/03 Due: 10/31/04

A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)

Phase: N/A Priority: Normal
NCT ID: NCT05766501 Org: User:
Start: 03/17/23 End: 09/06/28 Due: 09/06/29

Dose Optimization of Infliximab in Moderate to Severe Plaque Psoriasis (Study P05315)

Phase: N/A Priority: Normal
NCT ID: NCT00833053 Org: User:
Start: 10/31/09 End: 04/30/11 Due: 04/30/12

Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048)

Phase: N/A Priority: Normal
NCT ID: NCT00550771 Org: User:
Start: 07/16/07 End: 08/23/10 Due: 08/23/11

A Study to Determine the Efficacy and Safety of 2 Doses of Org 34517 as Adjunctive Therapy in Subjects With Psychotic Major Depression (28130)(P05845)

Phase: N/A Priority: Normal
NCT ID: NCT00212797 Org: User:
Start: 07/31/04 End: 07/31/06 Due: 07/31/07

MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027)

Phase: N/A Priority: Normal
NCT ID: NCT00482430 Org: User:
Start: 09/30/07 End: 10/31/08 Due: 10/31/09

Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00708500 Org: User:
Start: 08/31/08 End: 04/30/10 Due: 04/30/11